[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568793":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":60,"collaborators":26,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":26,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":26,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Hemanext","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A - Hemanext ONE system","EXPERIMENTAL","Hypoxic RBCs",[13],"Device: Hemanext ONE system",{"label":15,"type":16,"description":17,"interventionNames":18},"B - Conventional RBCs","ACTIVE_COMPARATOR","Conventional RBCs",[19],"Device: Conventional RBCs",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Hemanext ONE system","Hypoxic red blood cells",[9],null,{"type":22,"name":17,"description":28,"armGroupLabels":29,"otherNames":26},"Conventional manufactured Red blood cells",[15],[31],{"name":32,"affiliation":33,"role":34},"Håkon Reikvam, PhD, MD","Haukeland University Hospital","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Jill Badgasarian","CONTACT","(781) 301-7474","jill.bagdasarian@hemanext.com",[42],{"facility":33,"status":43,"city":44,"state":26,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Bergen","5021","Norway","NO",{"type":49,"coordinates":50},"Point",[51,52],5.32415,60.39299,{"lat":52,"lon":51},[55,59],{"name":56,"role":38,"phone":57,"phoneExt":26,"email":58},"Hakon Reikvam, PhD, MD","+4791 66 70 94","hakon.reikvam@uib.no",{"name":56,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100568793","comparison-of-hemanext-one-system-and-conventional-red-blood-cell-transfusion-100568793",false,"NCT06685848","Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion","Multi-Center, Randomized, Controlled Cross-Over Study to Evaluate Safety and Effectiveness of Hypoxic RBCs Processed With the Hemanext ONE System vs Conventional RBCs in Patients With Transfusion-Dependent Haematological Malignancies","Inclusion Criteria:\n\n* Male or female aged 18 or older\n* Patients with a documented diagnosis of a haematological malignancy requiring chronic transfusions.\n* If MDS patient, Have low risk or intermediate risk MDS per either IPSS-R (https:\u002F\u002Fwww.mds-foundation.org\u002Fipss-r-calculator\u002F) or IPSS-M (IPSS-M Risk Calculator (mds-risk-model.com))\n* If MDS patient, a bone marrow aspirate completed within the 6 months prior to study enrolment, and which did not show progression to higher risk MDS\n* Have RBC transfusion dependence (at least 2 RBC units \u002F8 weeks during the last 16 weeks)\n* Baseline RBC transfusion threshold of 9 g\u002FdL\n* ECOG (Eastern Cooperative Oncology Group) performance status \\< 3\n* Have signed the informed consent form and are willing to comply with the study visits and procedures\n* If on Iron Chelation Therapy, have been on a stable dose for ≥3 months prior to screening\n\nExclusion Criteria:\n\n* Have a life expectancy of less than 1 year\n* Have palpable splenomegaly (more than 3 cm below the mid clavicular line)\n* Have other associated causes of anemia (including auto-immune hemolysis or active hemorrhage, or progression to acute leukemia)\n* If prescribed erythropoiesis affecting disease modifying agents (e.g. G-CSF, erythropoietin), have not been on a stable dose for 90 days\n* Is currently taking Luspatercept or other investigational erythropoiesis affecting disease modifying agent\n* Have severe renal insufficiency with creatinine clearance (MDRD or CKD EPI) below 30ml\u002Fmin\n* Have lung disease with hypoxia or oxygen-dependent\n* Have severe coronary artery disease (including unstable angina or recent myocardial infraction) or severe heart failure (left ventricular ejection fraction less than 30%)\n* Have a history of cancer active in the previous 3 years, except local cervix cancer, or basal cell cutaneous carcinoma\n* Have a history of allo-immunization other than rhesus Kell that cannot be managed by the local blood bank\n* Are a female of child-bearing potential that is pregnant, planning to become pregnant in the next 14 months or breastfeeding\n* Are a patient under guardianship or curatorship\n* Are currently participating in another interventional study evaluating an erythropoiesis affecting disease modifying agent","ALL","18 Years",{"count":72,"type":73},24,"ESTIMATED","INTERVENTIONAL",[76],"NA","The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.",[79],"Hematologic Neoplasms",[81,82,83],"Transfusion","Red Blood Cells","Hypoxic","2026-01-06",{"date":86,"type":87},"2026-01-07","ACTUAL",{"date":89,"type":87},"2024-11-29",{"date":91,"type":73},"2026-12-15",{"name":5,"class":6},1]